LDH elevation

The mutation rates of the NOTCH1 gene [23.1% (3/13) vs 3.7% (6/162), P=0.021], the SOCS1 gene [15.4% (2/13) vs 0, P=0.005], and the KRAS gene [15.4% (2/13) vs 0, P=0.005] were all higher in the transformed group than those in the non-transformed group. Patients with MALT lymphoma who transformed to DLBCL are often accompanied by B symptoms, a higher MALT-IPI score, elevated LDH and multiple gene mutations, and the mutation frequencies of NOTCH1, SOCS1, and KRAS are higher.

In this nested case-control study of NDMM patients with RI, elevated LDH levels and pneumonia at diagnosis were identified as independent risk factors for early mortality in NDMM patients with renal impairment.

The PET-CT calculated total metabolic tumor volume correlated with the quantitative ctDNA result with a Pearson r factor of 0.49. In conclusion, ctDNA ddPCR BRAF testing is easily obtained and might be especially beneficial for patients diagnosed with a clinically aggressive disease, based on elevated LDH, higher PET-CT metabolic tumor volume, and younger age.

The GG (rs1801131-G/rs1801133-G) haplotype elevated LUAD risk by 1.53-fold (P = 0.022).ConclusionIn the Guangxi Zhuang cohort, the MTHFR rs1801131 GG genotype may represent a population-specific marker associated with LUAD susceptibility and poorer prognosis. Its combination with elevated LDH may provide supplementary information for risk stratification, although further validation in larger multicenter and multi-ethnic cohorts is required.

After a dose of ifosfamide/etoposide elsewhere, therapy was revised to ifosfamide, carboplatin, and etoposide plus brentuximab vedotin, with marked improvement by 2 cycles and cutaneous resolution by 5; she died of cardiopulmonary failure before the sixth cycle. This case underscores generous sampling, focused immunohistochemistry, and staging; negative ALK/EMA does not exclude systemic disease, and CD30-directed therapy can yield rapid cutaneous responses.

This review synthesizes the molecular mechanisms through which LDHA drives tumor progression, dissects its context-specific functions in CTC biology, and evaluates the translational potential of LDHA-targeted strategies, with a focused emphasis on oxamate, as a transformative anti-metastatic therapeutic paradigm. By filling a critical gap in synthesizing oxamate's distinct metabolic-immune regulatory actions, this work addresses an unmet need in the management of advanced, treatment-refractory cancers.

ASCT was associated with the most durable survival among consolidation strategies after R-MVP induction. These findings, derived from a large real-world, multi-institutional cohort, support ASCT as the preferred consolidation for eligible patients while underscoring the heterogeneity of current practice and the need for prospective validation.

The presence of DTCs in the BM is associated with the prognosis of AITL. Pleural effusion constitutes an independent adverse prognostic factor. Loss of CD7 correlates with shorter OS, and a profile combining CD3 expression, elevated LDH, and decreased HGB serves as a useful predictor of disease progression.

P2, N=30, Active, not recruiting, International Extranodal Lymphoma Study Group (IELSG) | Recruiting --> Active, not recruiting

P1/2, N=30, Recruiting, M.D. Anderson Cancer Center | Suspended --> Recruiting

P3, N=77, Active, not recruiting, Takeda | Recruiting --> Active, not recruiting

Therapeutic management followed an early, aggressive strategy, frequently utilizing cyclophosphamide (45.8%) and methotrexate (37.5%), with Janus kinase (JAK) inhibitors or rituximab employed in refractory cases. The observed dissociation between low CK/CRP and elevated LDH underscores the necessity for a high index of suspicion, with LDH serving as a superior marker for disease activity. While ILD presents a significant risk, early and intensive multi-modal intervention may yield superior survival outcomes in European patients compared to the historical mortality rates reported in Asian cohorts.